Eli Lilly-backed Maxion Therapeutics raises $72M Series A to advance its antibody approach
Maxion Therapeutics has secured $72 million in an oversubscribed Series A raise, with Eli Lilly pitching in, to advance its pipeline of antibody-based candidates. The proceeds should give Maxion enough runway through the end of ...
Maxion Therapeutics has secured $72 million in an oversubscribed Series A raise, with Eli Lilly pitching in, to advance its pipeline of antibody-based candidates.
The proceeds should give Maxion enough runway through the end of ...
